Overview

Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced NSCLC

Status:
Not yet recruiting

Trial end date:
2023-12-20

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy and safety of recombinant human endostatin /PD-1 mab combined with first-line chemotherapy in the treatment of driver gene negative advanced non-small cell lung cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Affiliated Cancer Hospital & Institute of Guangzhou Medical University

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Endostatins
Paclitaxel
Pemetrexed